Form4insider filings, from the source

SEC Form 4 · accession 0000899243-17-027007

X4 Pharmaceuticals, Inc · XFOR

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Terrance McGuire
Director · 10% Owner
Period of report
Nov 20, 2017
Accepted (ET)
Nov 20, 2017 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501697

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common StockF1,F2,F3Nov 20, 2017C18,848—A18,848ISee Footnotes
Common StockF1,F4Nov 20, 2017C367—A367ISee Footnote
Common StockF1,F5Nov 20, 2017C129—A129ISee Footnote
Common StockF1,F6Nov 20, 2017C188—A188ISee Footnote
Common StockF7,F2,F3Nov 20, 2017C243,385—A262,233ISee Footnotes
Common StockF7,F4Nov 20, 2017C4,743—A5,110ISee Footnote
Common StockF7,F5Nov 20, 2017C1,667—A1,796ISee Footnote
Common StockF7,F6Nov 20, 2017C2,433—A2,621ISee Footnote
Common StockF8,F2,F3Nov 20, 2017C317,376—A579,609ISee Footnotes
Common StockF8,F4Nov 20, 2017C6,185—A11,295ISee Footnote
Common StockF8,F5Nov 20, 2017C2,173—A3,969ISee Footnote
Common StockF8,F6Nov 20, 2017C3,173—A5,794ISee Footnote
Common StockF9,F2,F3Nov 20, 2017C110,312—A689,921ISee Footnotes
Common StockF9,F4Nov 20, 2017C2,150—A13,445ISee Footnote
Common StockF9,F5Nov 20, 2017C755—A4,724ISee Footnote
Common StockF9,F6Nov 20, 2017C1,102—A6,896ISee Footnote
Common StockF10,F2,F3Nov 20, 2017C631,041—A1,320,962ISee Footnotes
Common StockF10,F4Nov 20, 2017C12,298—A25,743ISee Footnote
Common StockF10,F5Nov 20, 2017C4,322—A9,046ISee Footnote
Common StockF10,F6Nov 20, 2017C6,310—A13,206ISee Footnote
Common StockF2,F3Nov 20, 2017P482,467$10.00A1,803,429ISee Footnotes
Common StockF4Nov 20, 2017P9,403$10.00A35,146ISee Footnote
Common StockF5Nov 20, 2017P3,305$10.00A12,351ISee Footnote
Common StockF6Nov 20, 2017P4,825$10.00A18,031ISee Footnote

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Series A-1 Convertible Preferred StockF2,F3,F1—Nov 20, 2017C64,329D——Common Stock18,8480I
Series A-1 Convertible Preferred StockF4,F1—Nov 20, 2017C1,254D——Common Stock3670I
Series A-1 Convertible Preferred StockF5,F1—Nov 20, 2017C441D——Common Stock1290I
Series A-1 Convertible Preferred StockF6,F1—Nov 20, 2017C643D——Common Stock1880I
Series A-2 Convertible Preferred StockF2,F3,F7—Nov 20, 2017C680,130D——Common Stock243,3850I
Series A-2 Convertible Preferred StockF4,F7—Nov 20, 2017C13,256D——Common Stock4,7430I
Series A-2 Convertible Preferred StockF5,F7—Nov 20, 2017C4,659D——Common Stock1,6670I
Series A-2 Convertible Preferred StockF6,F7—Nov 20, 2017C6,801D——Common Stock2,4330I
Series B Convertible Preferred StockF2,F3,F8—Nov 20, 2017C710,817D——Common Stock317,3760I
Series B Convertible Preferred StockF4,F8—Nov 20, 2017C13,854D——Common Stock6,1850I
Series B Convertible Preferred StockF5,F8—Nov 20, 2017C4,869D——Common Stock2,1730I
Series B Convertible Preferred StockF6,F8—Nov 20, 2017C7,108D——Common Stock3,1730I
Series C Convertible Preferred StockF2,F3,F9—Nov 20, 2017C221,638D——Common Stock110,3120I
Series C Convertible Preferred StockF4,F9—Nov 20, 2017C4,315D——Common Stock2,1500I
Series C Convertible Preferred StockF5,F9—Nov 20, 2017C1,516D——Common Stock7550I
Series C Convertible Preferred StockF6,F9—Nov 20, 2017C2,213D——Common Stock1,1020I
Series D Convertible Preferred StockF2,F3,F10—Nov 20, 2017C2,153,746D——Common Stock631,0410I
Series D Convertible Preferred StockF4,F10—Nov 20, 2017C41,976D——Common Stock12,2980I
Series D Convertible Preferred StockF5,F10—Nov 20, 2017C14,752D——Common Stock4,3220I
Series D Convertible Preferred StockF6,F10—Nov 20, 2017C21,537D——Common Stock6,3100I

Explanation of responses